Latest News

Keytruda® Active in Small Cell Lung Cancer

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, SCLC accounts for 10-20% of all lung cancers. Although progress … Continue reading “Keytruda® Active in Small Cell Lung Cancer”

read more

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each year in the U.S. roughly 22,000 women are diagnosed with ovarian cancer and more … Continue reading “Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer”

read more

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggests that treatment with Jakafi should be used much earlier in the course of a patient’s disease because it … Continue reading “5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis”

read more

Tagrisso®: New Standard of Care for Certain Lung Cancer

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed following prior therapy with an epidermal growth factor receptor (EGFR) inhibitor. Lung cancer remains the leading cause of cancer-related deaths in the … Continue reading “Tagrisso®: New Standard of Care for Certain Lung Cancer”

read more

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms (MPNs) are a related group of blood cancers. In these disorders, the bone marrow cells … Continue reading “Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia”

read more

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were recently presented at a plenary session of the 2016 annual meeting of the American Society of Hematology (ASH). Follicular lymphoma … Continue reading “Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma”

read more

FDA Grants Iclusig® Expanded Approval for CML

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive … Continue reading “FDA Grants Iclusig® Expanded Approval for CML”

read more

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO). Currently, HER2 is the only marker that can be … Continue reading “Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?”

read more

ASCO Recommends Early Integration of Palliative Care for Advanced Cancers

The American Society of Clinical Oncology (ASCO) has updated its guidelines on the integration of palliative care for patients diagnosed with advanced cancer, as well as their caretakers. In essence, the guidelines state that palliative care should be administered as early as possible for all patients diagnosed with advanced cancers, alongside their active treatment, as …

read more

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of … Continue reading “Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer”

read more

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or … Continue reading “Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions”

read more

Darzalex® Approved for Additional Indications in Multiple Myeloma

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and dexamethasone. Daratumumab is already approved … Continue reading “Darzalex® Approved for Additional Indications in Multiple Myeloma”

read more

Opdivo Approved for Advanced Head and Neck Cancer

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the head and neck cancer (SCCHN) that has spread to distant sites in the body and has progressed or … Continue reading “Opdivo Approved for Advanced Head and Neck Cancer”

read more

FDA Priority Review Granted for Midostaurin in Leukemia

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The diagnostic test to detect the FLT3 mutation has also been accepted for review by … Continue reading “FDA Priority Review Granted for Midostaurin in Leukemia”

read more

HOSPITAL ADDRESS

Leesburg or Sterling

HOSPITAL PHONE CONTACT

Fax: 1-855-831-9022 or 703-858-3111

Phone: (703)-858-3110

HOSPITAL EMAIL ADDRESS

info@gmail.com

info@yahoomail.com